Oxytocin does not modify the prolactin response to metoclopramide in normal women.
The present study was undertaken in order to establish whether oxytocin (OT) affects the dopaminergic control of PRL secretion in normal women during follicular, periovulatory and luteal phase of their menstrual cycle. For this purpose, 22 normal women were tested with a lower (1 mg) or higher (10 mg) dose of the dopaminergic antagonist metoclopramide (MCP) with or without the concurrent treatment with OT (2 IU injected plus 0.033 IU/min infused for 2 h). Since OT was found unable to modify the effect of either 1 or 10 mg MCP, in additional experiments the same doses of MCP and OT were administered after dopamine (0.04 micrograms/kg/min for 2 h) infusion. Also in these experimental conditions OT failed to modify the PRL response to MCP. These data argue against a role of OT in modulation of the dopaminergic control of PRL secretion in normal women.
Chiodera
P
P
Cattedra di Endocrinologia e Patologia Costituzionale, Università di Parma, Italy.
Volpi
R
R
Gramellini
D
D
Cigarini
C
C
Corradi
A
A
Cavazzini
U
U
Bianconi
L
L
Papadia
C
C
Caiazza
A
A
Capretti
L
L
D000328:Adult; D004298:Dopamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D005498:Follicular Phase / Q000502:physiology; D006801:Humans; D007275:Injections, Intravenous; D008183:Luteal Phase / Q000502:physiology; D008787:Metoclopramide / Q000494:pharmacology*; D010060:Ovulation / Q000502:physiology; D010121:Oxytocin / Q000494:pharmacology*; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D011388:Prolactin / Q000378:metabolism*; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology; D013997:Time Factors
D010121:Oxytocin; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D008787:Metoclopramide; D004298:Dopamine